SEO URLwww.firestrike.ai/deals/halozyme-therapeutics-takeda-pharmaceutical-company-acquisition-2026
acquisitionAnnounced · Jan 10, 2026BiotechnologySource · CredibleArticle · Factual
Takeda Pharmaceutical Company acquires Halozyme Therapeutics
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
—
Target
Halozyme Therapeutics
NASDAQ: HALO · San Diego, California
Acquirer
Takeda Pharmaceutical Company
Collaboration Agreement
Status
Announced
Takeda Pharmaceutical Company agreed to acquire Halozyme Therapeutics. Reported deal value: Undisclosed. Status: Announced. Sector: Biotechnology. Target headquarters context: San Diego, California, United States.
This page summarizes publicly available information about the transaction as of 2026-01-10. Figures and status may change as filings and press coverage update.
TAK In December 2025, Halozyme Therapeutics announced a global collaboration and exclusive license agreement granting Takeda access to its ENHANZE drug delivery technology for use with vedolizumab , an inflammatory bowel disease therapy marketed as ENTYVIO
Deal timeline
Announced
Jan 10, 2026 · ca.finance.yahoo.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Biotechnology. Figures and status may change as sources update.
Sources: ca.finance.yahoo.com · Primary article · FireStrike proprietary index